Cargando…

Do we still need renal biopsy in lupus nephritis?

The natural course of systemic lupus erythematosus (SLE) is characterized by periods of disease activity and remissions. Prolonged disease activity results in cumulative organ damage. Lupus nephritis is one of the most common and devastating manifestations of SLE. In the era of changing therapy to l...

Descripción completa

Detalles Bibliográficos
Autores principales: Haładyj, Ewa, Cervera, Ricard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918045/
https://www.ncbi.nlm.nih.gov/pubmed/27407281
http://dx.doi.org/10.5114/reum.2016.60214
_version_ 1782439050517413888
author Haładyj, Ewa
Cervera, Ricard
author_facet Haładyj, Ewa
Cervera, Ricard
author_sort Haładyj, Ewa
collection PubMed
description The natural course of systemic lupus erythematosus (SLE) is characterized by periods of disease activity and remissions. Prolonged disease activity results in cumulative organ damage. Lupus nephritis is one of the most common and devastating manifestations of SLE. In the era of changing therapy to less toxic regimens, some authors have stated that if mycophenolate mofetil can be used for the induction and maintenance treatment in all histological classes of lupus nephritis, renal biopsy can be omitted. This article aims to answer the question of what brings the bigger risk: renal biopsy or its abandonment.
format Online
Article
Text
id pubmed-4918045
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie
record_format MEDLINE/PubMed
spelling pubmed-49180452016-07-12 Do we still need renal biopsy in lupus nephritis? Haładyj, Ewa Cervera, Ricard Reumatologia Review Paper The natural course of systemic lupus erythematosus (SLE) is characterized by periods of disease activity and remissions. Prolonged disease activity results in cumulative organ damage. Lupus nephritis is one of the most common and devastating manifestations of SLE. In the era of changing therapy to less toxic regimens, some authors have stated that if mycophenolate mofetil can be used for the induction and maintenance treatment in all histological classes of lupus nephritis, renal biopsy can be omitted. This article aims to answer the question of what brings the bigger risk: renal biopsy or its abandonment. Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2016-06-03 2016 /pmc/articles/PMC4918045/ /pubmed/27407281 http://dx.doi.org/10.5114/reum.2016.60214 Text en Copyright © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2016 http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Review Paper
Haładyj, Ewa
Cervera, Ricard
Do we still need renal biopsy in lupus nephritis?
title Do we still need renal biopsy in lupus nephritis?
title_full Do we still need renal biopsy in lupus nephritis?
title_fullStr Do we still need renal biopsy in lupus nephritis?
title_full_unstemmed Do we still need renal biopsy in lupus nephritis?
title_short Do we still need renal biopsy in lupus nephritis?
title_sort do we still need renal biopsy in lupus nephritis?
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918045/
https://www.ncbi.nlm.nih.gov/pubmed/27407281
http://dx.doi.org/10.5114/reum.2016.60214
work_keys_str_mv AT haładyjewa dowestillneedrenalbiopsyinlupusnephritis
AT cerveraricard dowestillneedrenalbiopsyinlupusnephritis